GO-BRCA
Integrated Hereditary Ovarian Cancer Pilot
Stephanie Desmarais, Ruth Kohut, Renee Perrier: Hereditary Cancer Clinic, Genetic Services, Calgary Zone
Sarah Glaze, Pam Sweeney Gyne-Oncology Team, TBCC.

Background: Hereditary Cancer Clinic (HCC) Genetic Services, Calgary Zone

- 200 women are diagnosed with ovarian cancer each year in Alberta.
- 15-20% are due to a hereditary cancer gene mutation (majority: BRCA 1/2 mutation).
- For every woman with an identified genetic mutation, 2-5 close relatives are at high risk for inheriting the same gene.

Timely identification of a cancer gene can help:
- Guide ovarian cancer treatment,
- Direct screening & prevention strategies for patients and close relatives.

Important to genetic testing is informed consent.

Hereditary Cancer Clinic (HCC) provides HC risk assessment, counselling and genetic testing for individuals affected or at high risk for a hereditary cancer syndrome.

Our Challenge- Timely Access to Genetic Testing
To support informed consent for genetic testing, the traditional HCC model requires pre-test HCC genetic counselling.

Ovarian cancer referrals from the Gyne-Oncology team (GO) would be triaged & wait-listed between 0-12 months; posing an access barrier to timely genetic testing.

This GO-BRCA Pilot was driven by the need to change the existing model & address the exponential growth in HCC referrals with no added resources (The Angelina Effect).

Our HCC GO Shared Goal
Increase access to timely and seamless genetic testing for ALL women with ovarian cancer in Southern Alberta, while maintaining informed consent and patient satisfaction.


The GO-BRCA model transfers pre-test information & genetic testing tasks to the GO team.

Result disclosure, by telephone or 1:1 genetic counselling, remains with HCC.

To support success:
- Physician package & in-service training was provided to the GO team.
- Augmented patient materials, including an educational brochure & a 5 minute video**, was provided on a tablet at the patient’s GO appointment.

Outcomes

1. Improved collaboration and coordinated care.
2. Satisfaction and acceptability of GO-BRCA model from both the patients and the GO team.
3. Timely access to genetic testing for all ovarian cancer patients.
4. Improved HCC capacity.
5. Enhanced competencies of oncologists and nurses to provide genetic testing within their medical setting; optimizing their scope of practice.

As measured by:
- Pre & Post-Pilot Surveys
- Comparison of time from HCC referral to results disclosure between a pre-GO-BRCA cohort (N = 60) and study group.
- Number of pre-test HCC appointments no longer required.

Successes, Limitations & Challenges

- GO BRCA model reduced wait time to genetic testing results, from a mean of 305 to 158 days, while supporting patient expectations, informed choice and building GO team competencies. Lab turnaround time was beyond the scope/control of pilot.
- Over 100 hours of HCC appointment times freed for other referrals.
- Success contributed to small and motivated teams & dedicated pilot funding for resource support.
- Challenge of adding additional complex genetic testing discussion in an already busy GO clinic.
- Assumption that all women with ovarian cancer were included given TBCC GO team’s catchment.

Next Steps & Vision for the Future

- This model is now standard of care for ovarian cancer patients in Calgary.
- In February 2017, a “Provincial 13-Gene Breast/Ovarian Cancer Gene Panel” was launched by Genetic Lab Services.
- In June 2017, the GO team received an education in-service and GO-BRCA was expanded to include the full panel.

- Expansion to selected breast cancer patients (e.g. < 35 yr; triple negative) is under discussion.
- The model opens opportunities to expand provincially and to other genetic conditions.

ACKNOWLEDGEMENTS: Drs. Pam Chu, Jill Nation, Gregg Nelson, Prafull Ghatage; Rhiannon Bennoi, CMO Office and HCC Volunteers